Dubois Wil
Diabetes Self Manag. 2016 May-Jun;33(3):88-91.
Recent FDA approvals introduce both cheaper insulin in the form of a biosimilar and lipid-lowering agents with prices that rival the cost of cancer drugs. They also give us brand new ways to lower blood glucose and repair the damage done when glucose control fails. Hundreds more are in the pipeline, of which one or two per year will win marketing approval from the FDA.
美国食品药品监督管理局（FDA）近期批准了一款价格更为亲民的生物类似药胰岛素以及价格可与抗癌药物相媲美的降血脂药物。这些批准还为我们提供了全新的降低血糖以及修复血糖控制不佳时所造成损害的方法。还有数百种药物正在研发中，其中每年会有一两种获得FDA的上市批准。
